title: Leptomeningeal disease in oligodendroglial tumors: a population-based study.
abstract: In this population-based study, we determined the frequency and clinical characteristics of leptomeningeal disease (LMD) developing in the context of oligodendroglial tumors (oligodendrogliomas and oligoastrocytomas). LMD occurred in only 3.9% (8/204) of oligodendroglial tumors and in patients with more recurrences [mean 2.88 vs. 1.27 in LMD and non-LMD, respectively (p = 0.001)]. In contrast to LMD from systemic solid tumors, the median survival following the diagnosis of LMD in oligodendroglial tumors was surprisingly long at 22 months (95% CI 11-33 months). Treatment with oral chemotherapy seemed as effective as more aggressive treatments (e.g. repeat RT or intrathecal chemotherapy) in these patients.
authors.affiliation: Clark H. Smith Brain Tumor Center, Tom Baker Cancer Center, Alberta Health Services, HRIC 2AA07, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada.
authors.forename: Gloria
authors.initials: G
authors.lastname: Roldán
authors.forename: Jennifer
authors.initials: J
authors.lastname: Chan
authors.forename: Misha
authors.initials: M
authors.lastname: Eliasziw
authors.forename: J Gregory
authors.initials: JG
authors.lastname: Cairncross
authors.forename: Peter A
authors.initials: PA
authors.lastname: Forsyth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000401:mortality; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics*; D018672:Community Health Planning; D018450:Disease Progression; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008578:Meninges / Q000473:pathology*; D008875:Middle Aged; D009837:Oligodendroglioma / Q000453:epidemiology* / Q000235:genetics / Q000401:mortality; D012189:Retrospective Studies; D055815:Young Adult